AXSM

AI Memo

Axsome Therapeutics

As of 2026-10-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

November 2 results test AUVELITY launch uptake • 2026-11-02

Base target: $180 / p=50% prob

Biggest risk

The launch indicator is early and not proof of durable revenue. Second-quarter SG&A rose to $208.1 million from $130.3 million a year earlier, and Axsome recorded a $51.3 million net loss. Commercial spending may outrun uptake; the AXS-12 decision remains uncertain. [#SEC-8K-2026-08-10]

Invalidation

Break below $100 or thesis failure.

What would change my mind?

Second-quarter net product revenue grew 46% year over year to $218.4 million, while early AUVELITY launch prescription indicators were encouraging. Sustained uptake could support commercial leverage, with AXS-12 adding a separate regulatory opportunity. [#SEC-8K-2026-08-10]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-14

Base target

$180

p=50%

Bull target

$240

p=25%

Bear target

$100

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-quarter net product revenue grew 46% year over year to $218.4 million, while early AUVELITY launch prescription indicators were encouraging.
Sustained uptake could support commercial leverage, with AXS-12 adding a separate regulatory opportunity.
[#SEC-8K-2026-08-10]

BearKey bullets

AUVELITY Alzheimer's-agitation launch prescriptions may not translate into durable, reimbursed sales; payer access and execution remain important.
[#SEC-8K-2026-08-10]
AXS-12 faces FDA decision risk, and initiated solriamfetol ADHD Phase 3 trials carry clinical timing and outcome risk.

WatchKey bullets

November 2 results test AUVELITY launch uptake

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $180 (p=50%)

Target spread vs base: +33% / -44%

Scenario probabilities

Bull Target: $240 (p=25%)Base Target: $180 (p=50%)Bear Target: $100 (p=25%)

Commentary

The packet contains limited recent news and no usable social, options, short-interest, or employee-sentiment measurements; the zero-valued fields above denote unavailable data, not neutral observations. A September headline describes a positive analyst reaction, but the underlying target revision is unverified and does not drive the thesis. No post-November-results reaction exists as of this report. The deterministic prior is positive, but the 32.1% uncertainty score, early launch data, and loose peers warrant monitoring rather than a high-conviction call.

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-quarter net product revenue grew 46% year over year to $218.4 million, while early AUVELITY launch prescription indicators were encouraging.
Sustained uptake could support commercial leverage, with AXS-12 adding a separate regulatory opportunity.
[#SEC-8K-2026-08-10]

Scenarios

Bull Target (Scenario probability)

$240 / p=25% prob

Base Target (Scenario probability)

$180 / p=50% prob

Bear Target (Scenario probability)

$100 / p=25% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-02
November 2 results test AUVELITY launch uptake
Axsome scheduled third-quarter results for November 2. The decision-relevant test is whether AUVELITY's June Alzheimer's-agitation launch converts early prescription growth into sustained sales. Second-quarter AUVELITY sales were $180.3 million, up 51% year over year; the company reported a 126% increase in new-to-brand prescriptions among patients aged 65 or older during the launch's first eight weeks versus the comparable prior-quarter period. [#PR-EARNINGS-2026-10-07] [#8-K-2026-08-10] [#SEC-8K-2026-08-10]
Prob 55.00% • Move 12.00% • Priced-in 40.00%
EVENT2027-05-01
AXS-12 FDA decision
Axsome reported that the FDA accepted its AXS-12 application for cataplexy in narcolepsy and set a May 1, 2027 target action date. Approval could expand the commercial portfolio; a delay or rejection would weaken the pipeline case. [#SEC-8K-2026-08-10]
Prob 55.00% • Move 15.00% • Priced-in 35.00%

Risks

AUVELITY Alzheimer's-agitation launch prescriptions may not translate into durable, reimbursed sales; payer access and execution remain important. [#SEC-8K-2026-08-10]
AXS-12 faces FDA decision risk, and initiated solriamfetol ADHD Phase 3 trials carry clinical timing and outcome risk. [#SEC-8K-2026-08-10]
Cash and equivalents were $319.9 million at June 30, 2026. Management's view that cash can fund operations into cash-flow positivity depends on its current operating plan. [#SEC-8K-2026-08-10]
Commercial expansion increased second-quarter SG&A materially, while the company remained loss-making. [#SEC-8K-2026-08-10]

Peers

Symbol	Summary
ARWR	Similar market-cap biotech candidate, but a loose operating comparison: its development exposure does not directly benchmark Axsome's marketed CNS portfolio.
CYTK	Similar market-cap biopharma candidate, but a loose therapeutic comparison; use only as a broad pipeline-risk reference.
GILD	Established commercial biopharma reference, but far larger and more diversified than Axsome; not a direct valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

ARWR

Similar market-cap biotech candidate, but a loose operating comparison: its development exposure does not directly benchmark Axsome's marketed CNS portfolio.

CYTK

Similar market-cap biopharma candidate, but a loose therapeutic comparison; use only as a broad pipeline-risk reference.

GILD

Established commercial biopharma reference, but far larger and more diversified than Axsome; not a direct valuation multiple.